Lee Jiwon, Han Dong Woo, Kim Na Young, Kim Keun-Su, Yang Yunil, Yang Juyeon, Lee Hye Sun, Kim Myoung Hwa
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea.
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Drug Des Devel Ther. 2024 Jan 23;18:121-132. doi: 10.2147/DDDT.S441622. eCollection 2024.
Remimazolam is a newly developed ultra-short-acting benzodiazepine. We compared overall functional recovery, including the postoperative Quality of Recovery-15 (QoR-15) questionnaire scores, between balanced inhalational anesthesia using sevoflurane and total intravenous anesthesia (TIVA) with remimazolam in patients undergoing anterior cervical discectomy and fusion (ACDF).
Seventy-two patients were randomized to the remimazolam (group R) or sevoflurane (group S) group. The primary outcome was the total QoR-15 score on postoperative day (POD) 1. We also assessed the total QoR-15 score on POD2, sub-scores of the QoR-15, perioperative parameters, and postoperative recovery profiles. Group-time interaction effects on the QoR-15 and its sub-scores were analyzed using a linear mixed model.
The total QoR-15 score on POD1 (120.2 in group R vs 114.3 in group S, =0.189) was not statistically different between the groups. There were no significant group-time interaction effects on total QoR-15 scores. Instead, patients in group R showed significantly better sub-scores in psychological and postoperative nausea and vomiting (PONV) items on POD1, as well as a lower degree of PONV, than those in group S. Among the five dimensions of the QoR-15, a significant group-time interaction effect was observed for psychological support. Group R showed significantly less changeability in blood pressure and heart rate with a lower dose of intraoperatively administered vasopressor than group S.
Considering QoR-15, including PONV reduction, and intraoperative hemodynamic stability, remimazolam can be used as the novel and safe anesthetic agent for maintaining general anesthesia instead of sevoflurane in patients undergoing ACDF.
瑞马唑仑是一种新研发的超短效苯二氮䓬类药物。我们比较了在接受颈椎前路椎间盘切除融合术(ACDF)的患者中,使用七氟醚的平衡吸入麻醉与使用瑞马唑仑的全静脉麻醉(TIVA)之间的整体功能恢复情况,包括术后恢复质量-15(QoR-15)问卷评分。
72例患者被随机分为瑞马唑仑组(R组)或七氟醚组(S组)。主要结局指标是术后第1天(POD1)的QoR-15总分。我们还评估了POD2的QoR-15总分、QoR-15的子评分、围手术期参数以及术后恢复情况。使用线性混合模型分析组间时间交互作用对QoR-15及其子评分的影响。
两组之间POD1的QoR-15总分(R组为120.2,S组为114.3,P = 0.189)无统计学差异。组间时间交互作用对QoR-15总分无显著影响。相反,R组患者在POD1的心理、术后恶心呕吐(PONV)项目上的子评分显著优于S组,且PONV程度更低。在QoR-15的五个维度中,观察到心理支持方面存在显著的组间时间交互作用。与S组相比,R组术中使用血管升压药剂量更低,血压和心率的变异性显著更小。
考虑到QoR-15,包括减少PONV以及术中血流动力学稳定性,在接受ACDF的患者中,瑞马唑仑可作为新型安全的麻醉药物用于维持全身麻醉,替代七氟醚。